HYPR

Hyperfine sells the Swoop portable ultra-low-field brain MRI — a genuinely differentiated, FDA-cleared product with a claimed >$16B US TAM. But the numbers say the commercialization ramp has stalled, not inflected. Revenue went $1.5M→$6.8M→$11.0M→$12.9M→$13.6M, so FY2025 growth collapsed to just +5.2% after years of near-doubling. A pre-scale medtech decelerating to single digits is the opposite of what the bull case needs; management itself flags in the 10-K that it 'may never generate revenue sufficient to offset our expenses' and has 'not yet achieved wide market acceptance' or 'refined our sales model.'

The financial condition compounds the risk. Net loss was -$35.6M on $13.6M of revenue (a -262% net margin), operating cash burn was -$27.9M, and the company holds only $35.1M of cash — roughly 15 months of runway before a raise. With 81.8M shares already up +13% YoY and a -$330M accumulated deficit, further equity issuance is close to inevitable and would dilute a $106M-cap holder heavily; the Risk Factors explicitly warn losses will 'continue.' The balance sheet is otherwise clean (liabilities/equity 0.35x, little debt), and gross margin of 49.8% (improving +14.6%) plus a 28% narrower burn are the two real positives — but they don't offset a top line that isn't growing into the fixed cost base.